Skip to content

Beyond the needle: The future of intratumoral therapy

November 5, 2026 · 21 min

Show notes

In this episode of Denatured, you’ll hear from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratumoral therapies trigger systemic anti-cancer immunity from a local injection, and redefine a foundational platform in immuno-oncology.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Lewis Bender, President & CEO, Intensity Therapeutics

Paul-Peter Tak, President, CEO and Board Director, Candel Therapeutics

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.



All episodes of BioSpace

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.